R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage
R&A PSYINS, an independent insurance broker that provides insurance to the psychedelic industry, announced a strategic partnership with
This landmark partnership was established to address a paramount issue facing psychedelic medicinal businesses. While more state legislators are pushing forward psychedelic policy reform – opening the door for more therapists and clinicians, retreats, and investors to enter the space – it is extremely difficult for psychedelic medicinal businesses to access insurance in this current hardened insurance market, leaving them exposed to a wide spectrum of risks.
Psychedelic therapies are in the highest risk pool for malpractice and other claims. Ketamine clinics, therapists and other practitioners need to understand, mitigate, and protect themselves from these perils. For companies that manufacture, test and distribute psychedelics for medicinal purposes, there are a host of additional risks, particularly if the goal is to go public. In response, R&A PSYINS developed a risk management program that offers specialty lines of business and medical malpractice insurance policies, including Professional Liability/Errors & Omissions, General Liability, Directors & Officers Liability, Product Liability, IP Defense/Enforcement, Cyber Defense/Data Breach and Workers’ Compensation coverage.
Nucleus, which is wholly owned by the venture capital firm, Iter Investments, is comprised of technology, data, and media assets intended to deliver intelligence, education, and opportunities to psychedelic industry stakeholders. The company’s acquisition of Psychedelic Invest and Neuly in 2022 was the foundation for its robust ecosystem. With its proprietary search technology, vast database, and suite of educational assets, Nucleus is helping to propel transformative health treatments forward.
“Both of our companies are at the forefront of the psychedelic medicinal movement,” said
This new partnership will benefit all stakeholders in Nucleus’ robust ecosystem by providing them access to psychedelic industry insurance that will ensure they are fully protected and in compliance with state and federal HIPPA regulations.
“We couldn’t be more excited to partner with a company like R&A PSYINS,” said
###
About R&A PSYINS
R&A PSYINS is a division of
+1 401-368-6655
[email protected]
Visit us on social media:
LinkedIn



Aspire General Insurance Appoints Byron Storms as CEO and Chairman
MetLife Named One of America’s Most Just Companies
Advisor News
- Retirement control is top success measure for middle class, ACLI says
- Industry groups applaud House passage of Financial Exploitation Prevention Act
- Younger workers more likely to be eligible for a retirement plan after changing jobs
- Bank of America community event unpacks sales tax hike, small business struggles
- CONGRESSMAN VALADAO DEMANDS ANSWERS FROM CALIFORNIA OVER HEALTHCARE TAX HIKE
More Advisor NewsAnnuity News
- Jackson Named InvestmentNews 2026 Annuities Provider of the Year
- State Farm’s agency overhaul: What distribution can learn
- IRI, ACLI express support for CLEAR Forms Act
- A new era at the Federal Reserve
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Tuesday Session
More Annuity NewsHealth/Employee Benefits News
- How health insurance brokers can use AI to thrive
- Opinion: Improving how we deliver healthcare in Idaho
- Kansas City won’t escape the US debt crisis. Here’s what we must do now | Opinion
- High costs of coverage, LTC crisis continue to shape health care ecosystem
- Two disability policies, two purposes
More Health/Employee Benefits NewsLife Insurance News
- Jackson Named InvestmentNews 2026 Annuities Provider of the Year
- Corebridge adds index strategies, growth potential to Max Accumulator+ III
- Estate planning 2.0: How ILITs can create liquidity
- AM Best Affirms Credit Ratings of Misr Insurance Company
- State Farm’s agency overhaul: What distribution can learn
More Life Insurance News